精密医療市場：製品タイプ、用途、エンドユーザー別-2025-2030年の世界予測

精密医療市場は、2024年には1,405億4,000万米ドルとなり、2025年にはCAGR 11.44%で1,559億米ドルに成長し、2030年には2,692億米ドルに達すると予測されています。

プレシジョンメディシンは、個々の患者を治療戦略の中心に据えるという、ヘルスケア提供方法のパラダイムシフトを意味します。最近のゲノム、デジタルヘルス、バイオテクノロジーの動向は、患者一人ひとりの特性に合わせた治療法や診断法の開発を可能にしています。本レポートでは、プレシジョン・メディシンの現状と将来展望を掘り下げた詳細なエグゼクティブサマリーを提供し、業界を再定義する新たな動向と機会を明らかにします。

分析の焦点は、治療と診断におけるブレークスルーを強調するだけでなく、この急速に進化する分野を支える社会経済的・規制的要因を探ることにもあります。そうすることで、本レポートは業界の専門家や意思決定者に業界情勢を包括的に理解させ、市場の方向性や、組織がこの複雑な領域をナビゲートする際に考慮すべきステップについての理解を深めることを目的としています。

この包括的な概観は、最先端の調査と実際的な実行のバランスをとった革新的な戦略を求めるものです。様々な変革的シフト、セグメンテーションの洞察、地域のダイナミクスを旅するにつれ、精密医療が単なるトレンドではなく、世界中のヘルスケアシステムの根本的な再構築であることが明らかになります。

プレシジョン・メディシンの変革的シフト診断と治療の新時代

プレシジョン・メディシンの情勢は、病気の診断と治療の方法を一変させるような変革の時を迎えています。高スループットゲノムシーケンスの採用、分子診断学の進歩、臨床的意思決定における人工知能の統合は、より正確でタイムリーな介入への道を開いています。このようなシフトは、遺伝的、環境的、ライフスタイル的要因を考慮した個別化治療計画の重視の高まりによって特徴付けられ、個々の患者プロファイルにより効果的に適合させることができる治療につながっています。

世界市場全体では、包括的なデータ分析と臨床研究を統合する動きが顕著になっています。この統合により、リアルタイムのデータが治療の選択に役立ち、臨床試験を強化し、最終的にはより効率的なヘルスケア提供につながる強固なエコシステムが醸成されつつあります。この進化は、デジタルヘルスプラットフォームと精密診断への多額の投資によって支えられており、従来の画一的なアプローチから、より患者中心のソリューションへの決定的な変化を示しています。

技術の進歩はまた、継続的なモニタリングと介入を必要とする慢性疾患や病状の管理に不可欠な予測分析において、より洗練されたアプローチを可能にしています。ヘルスケアプロバイダーは、このような変革的なシフトに適応するため、データ主導の洞察にますます頼ってケア経路を最適化し、それによってコストを削減し、患者の転帰を改善するようになっています。このような精密さへのシフトは、治療プロトコルを再定義するだけでなく、早期発見とオーダーメイドの治療戦略に主眼を置く予防医療の時代も到来させつつあります。

進化する精密医療市場の主なセグメンテーション洞察

プレシジョンメディシンの市場は、製品タイプ、アプリケーション、エンドユーザーによって複雑にセグメント化されており、それぞれが全体像に独自の次元をもたらしています。製品タイプを深く掘り下げると、市場は診断、ソフトウェアとデータ分析、治療薬にまたがって調査されていることがわかる。精密医療に不可欠な柱である診断薬は、コンパニオン診断、遺伝子検査、リキッドバイオプシー、分子診断、ポイントオブケア検査など複数のアプローチにまたがっています。これらの方法は、患者の分子プロファイルを詳細に理解することで、疾患の早期発見や治療方針の決定に役立っています。

これと並行して、この市場における治療薬は、いくつかの先進的な治療方法にわたって分析されています。これには、細胞療法、遺伝子療法、免疫療法、タンパク質補充療法、RNAベース療法、標的療法などが含まれます。治療分野では、さまざまな疾患の根底にある遺伝子異常を正確に標的とする治療法に焦点を当てることで、個別化治療の重要性を強調しています。ソフトウェアとデータ解析は、これらのアプローチをさらに補完し、複雑なデータセットの集約と解釈を可能にして、診断と治療の両プロセスを強化します。

アプリケーションに基づくセグメンテーションを考慮すると、精密医療は、様々な重篤な疾患への対応において大きな進出を果たしています。同市場は、自己免疫疾患、心臓病学、感染症、神経学、腫瘍学、希少疾患、遺伝性疾患、呼吸器疾患などに及ぶアプリケーションを包含しています。この幅広い応用範囲は、多様な患者集団に共通する健康問題と複雑な健康問題の両方に対処する精密医療の多用途性と拡大する可能性を浮き彫りにしています。

セグメンテーション分析は、バイオ医薬品およびバイオテクノロジー企業、診断研究所、病院および診療所、研究機関を含むエンドユーザーの調査によってさらに充実したものとなっています。これらの各セグメントは、エコシステムにおいて重要な役割を果たしており、積極的にイノベーションを推進し、新しい精密医療ソリューションの臨床への統合を促進しています。これらのセグメンテーションを総合すると、あるセグメントにおける進歩がしばしば他のセグメントにおける進歩を触媒し、最終的に精密医療の全体的な勢いに拍車をかけるという、市場の相互関連性がよくわかる。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加と個別化治療オプションの需要
    • 患者とヘルスケア従事者の間で精密医療の利点に関する認識が高まっている
    • 技術の進歩を目的とした政府の取り組みと官民資金の増加
  • 抑制要因
    • 開発コストが高く、精密医療の標準化されたプロトコルとガイドラインが不足している
  • 機会
    • 患者の診断と治療を改善するために、精密医療に人工知能を統合する
    • 市場ベンダーと調査機関の協力による精密医療の推進
  • 課題
    • 患者のプライバシーと個人情報および健康情報の機密性に関する懸念
• 市場セグメンテーション分析
  • 製品タイプ：疾患の分子および遺伝学的基盤を正確に特定する基礎的な役割により、診断の利用が増加
  • 応用：個々の遺伝的、分子的、臨床的プロファイルに基づいて治療アプローチをカスタマイズできるため、腫瘍学では精密医療が広く使用されています。
  • エンドユーザー：バイオ医薬品およびバイオテクノロジー企業における精密医療の採用による標的治療の開発
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 精密医療市場：製品タイプ別

• 診断
  • コンパニオン診断
  • 遺伝子検査
  • 液体生検
  • 分子診断
  • ポイントオブケア検査
• ソフトウェアとデータ分析
• 治療薬
  • 細胞療法
  • 遺伝子治療
  • 免疫療法
  • タンパク質補充療法
  • RNAベースの治療法
  • 標的療法

第7章 精密医療市場：用途別

• 自己免疫疾患
• 心臓病学
• 感染症
• 神経学
• 腫瘍学
• 希少疾患および遺伝性疾患
• 呼吸器疾患

第8章 精密医療市場：エンドユーザー別

• バイオ医薬品・バイオテクノロジー企業
• 診断検査室
• 病院と診療所
• 調査機関

第9章 南北アメリカの精密医療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の精密医療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの精密医療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Aranscia, LLC
• AstraZeneca PLC
• biocrates life sciences ag
• bioMerieux S.A.
• Bristol-Myers Squibb Company
• Caris Life Sciences
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• Guardant Health, Inc.
• healthOme, Inc.
• Hitachi High-Tech Corporation
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• Medtronic PLC
• Merck KGaA
• N-Power Medicine, Inc.
• Natera Inc.
• NeoGenomics, Inc.
• Novartis AG
• Pfizer, Inc.
• Precision Medicine Group, LLC
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Sanofi SA
• Strata Oncology, Inc.
• Tempus AI, Inc.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• ZS Associates, Inc.

LIST OF FIGURES

• FIGURE 1. PRECISION MEDICINE MARKET MULTI-CURRENCY
• FIGURE 2. PRECISION MEDICINE MARKET MULTI-LANGUAGE
• FIGURE 3. PRECISION MEDICINE MARKET RESEARCH PROCESS
• FIGURE 4. PRECISION MEDICINE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRECISION MEDICINE MARKET DYNAMICS
• TABLE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PRECISION MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. CHINA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. CHINA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 82. CHINA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 83. CHINA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. CHINA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. INDIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. INDIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 87. INDIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 88. INDIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. JAPAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. MALAYSIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 102. MALAYSIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. PHILIPPINES PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 107. PHILIPPINES PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 108. PHILIPPINES PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. SINGAPORE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 112. SINGAPORE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 113. SINGAPORE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. SINGAPORE PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. SOUTH KOREA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 117. SOUTH KOREA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 118. SOUTH KOREA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. SOUTH KOREA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. TAIWAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 122. TAIWAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 123. TAIWAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. TAIWAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. THAILAND PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 127. THAILAND PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 128. THAILAND PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. THAILAND PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. VIETNAM PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 132. VIETNAM PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 133. VIETNAM PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. VIETNAM PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. DENMARK PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 143. DENMARK PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 144. DENMARK PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. DENMARK PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. EGYPT PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 148. EGYPT PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 149. EGYPT PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. EGYPT PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. FINLAND PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 153. FINLAND PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 154. FINLAND PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. FINLAND PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. FRANCE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 158. FRANCE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 159. FRANCE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. FRANCE PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. GERMANY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 163. GERMANY PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 164. GERMANY PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. GERMANY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. ISRAEL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 168. ISRAEL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 169. ISRAEL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. ISRAEL PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. ITALY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. ITALY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 173. ITALY PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 174. ITALY PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. ITALY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NETHERLANDS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 178. NETHERLANDS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 179. NETHERLANDS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NETHERLANDS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. NIGERIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 183. NIGERIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 184. NIGERIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. NIGERIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. NORWAY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 188. NORWAY PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 189. NORWAY PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. NORWAY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. POLAND PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. POLAND PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 193. POLAND PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 194. POLAND PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. POLAND PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. QATAR PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. QATAR PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 198. QATAR PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 199. QATAR PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. QATAR PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. RUSSIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 203. RUSSIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 204. RUSSIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. RUSSIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SAUDI ARABIA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 208. SAUDI ARABIA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 209. SAUDI ARABIA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SAUDI ARABIA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 214. SOUTH AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SPAIN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 218. SPAIN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 219. SPAIN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SPAIN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. SWEDEN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 223. SWEDEN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 224. SWEDEN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. SWEDEN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. SWITZERLAND PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 228. SWITZERLAND PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 229. SWITZERLAND PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. SWITZERLAND PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. TURKEY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 233. TURKEY PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 234. TURKEY PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. TURKEY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED ARAB EMIRATES PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 238. UNITED ARAB EMIRATES PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 239. UNITED ARAB EMIRATES PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. UNITED ARAB EMIRATES PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 242. UNITED KINGDOM PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 243. UNITED KINGDOM PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 244. UNITED KINGDOM PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. UNITED KINGDOM PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 247. PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

The Precision Medicine Market was valued at USD 140.54 billion in 2024 and is projected to grow to USD 155.90 billion in 2025, with a CAGR of 11.44%, reaching USD 269.20 billion by 2030.

Precision medicine represents a paradigm shift in the way healthcare is delivered, placing the individual patient at the center of treatment strategies. Over recent years, advances in genomics, digital health, and biotechnology have converged to enable the development of therapies and diagnostics that are tailored to the unique characteristics of each patient. This report provides an in-depth executive summary that delves into the current state and future prospects of precision medicine, uncovering the emerging trends and opportunities that are set to redefine the industry.

The focus of the analysis is not only to highlight the breakthroughs in treatment and diagnostics but also to explore the socio-economic and regulatory factors that underpin this rapidly evolving field. In doing so, the report aims to equip industry experts and decision-makers with a comprehensive view of the landscape, fostering a deeper understanding of where the market is headed and what steps organizations should consider when navigating this complex arena.

This comprehensive overview serves as a call for innovative strategies that balance cutting-edge research with pragmatic execution. As we journey through the various transformative shifts, segmentation insights, and regional dynamics, it becomes clear that precision medicine is not merely a trend, but a fundamental reimagining of healthcare systems around the world.

Transformative Shifts in Precision Medicine: A New Era of Diagnosis and Treatment

The landscape of precision medicine is undergoing transformative shifts that are revolutionizing how diseases are diagnosed and treated. The adoption of high-throughput genomic sequencing, advancements in molecular diagnostics, and the integration of artificial intelligence in clinical decision-making are paving the path for more accurate and timely interventions. These shifts are characterized by an increased emphasis on personalized treatment plans that consider genetic, environmental, and lifestyle factors, leading to therapies that can be more effectively matched to individual patient profiles.

Across the global market, there is a significant move towards integrating comprehensive data analytics with clinical research. This integration is fostering a robust ecosystem where real-time data informs treatment choices, enhances clinical trials, and ultimately leads to more efficient healthcare delivery. The evolution is supported by substantial investments in digital health platforms and precision diagnostics, signaling a definitive change from traditional one-size-fits-all approaches to more patient-centric solutions.

Technological advancements are also enabling more sophisticated approaches in predictive analytics, which are crucial in managing chronic diseases and conditions that require ongoing monitoring and intervention. As healthcare providers adapt to these transformative shifts, they are increasingly relying on data-driven insights to optimize care pathways, thereby reducing costs and improving patient outcomes. This shift towards precision is not only redefining treatment protocols but is also launching an era of preventative care where the primary focus is on early detection and tailored therapeutic strategies.

Key Segmentation Insights in the Evolving Precision Medicine Market

The market for precision medicine is intricately segmented by product type, application, and end user, each bringing unique dimensions to the overall landscape. A deep-dive into product type reveals that the market is studied across diagnostics, software and data analytics, and therapeutics. Diagnostics, an essential pillar in precision medicine, spans multiple approaches such as companion diagnostics, genetic testing, liquid biopsy, molecular diagnostics, and point-of-care testing. These methods are instrumental in early disease detection and guiding treatment decisions by providing a granular understanding of a patient's molecular profile.

In parallel, therapeutics in the market are analyzed across several advanced treatment modalities. These include cell therapy, gene therapy, immunotherapy, protein replacement therapy, RNA-based therapy, and targeted therapy. The therapeutic segment underscores the importance of personalized treatment by focusing on modalities that precisely target the underlying genetic anomalies of various diseases. Software and data analytics further complement these approaches, enabling the aggregation and interpretation of complex datasets to bolster both diagnostic and therapeutic processes.

When considering the segmentation based on application, precision medicine has made significant inroads in addressing a range of critical conditions. The market encompasses applications spanning autoimmune diseases, cardiology, infectious diseases, neurology, oncology, rare and genetic disorders, as well as respiratory diseases. This broad spectrum of applications highlights the versatility and expansive potential of precision medicine in addressing both common and complex health issues across a diverse array of patient populations.

The segmentation analysis is further enriched by an exploration of end users, which include biopharmaceutical and biotechnology companies, diagnostic laboratories, hospitals and clinics, as well as research institutes. Each of these segments plays a vital role in the ecosystem, actively driving innovation and facilitating the integration of novel precision medicine solutions into clinical practice. Collectively, these segmentation insights illustrate the interconnected nature of the market, where advancements in one segment often catalyze progress in others, ultimately fueling the overall momentum of precision medicine.

Based on Product Type, market is studied across Diagnostics, Software & Data Analytics, and Therapeutics. The Diagnostics is further studied across Companion Diagnostics, Genetic Testing, Liquid Biopsy, Molecular Diagnostics, and Point-of-Care Testing. The Therapeutics is further studied across Cell Therapy, Gene Therapy, Immunotherapy, Protein Replacement Therapy, RNA-Based Therapy, and Targeted Therapy.

Based on Application, market is studied across Autoimmune Diseases, Cardiology, Infectious Diseases, Neurology, Oncology, Rare & Genetic Disorders, and Respiratory Diseases.

Based on End User, market is studied across Biopharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes.

Key Regional Insights: Global Dynamics Shaping the Precision Medicine Arena

The regional landscape of the precision medicine market provides a multifaceted view of how various economic, regulatory, and cultural factors drive innovation and adoption. In the Americas, significant investment in biotechnology research coupled with robust healthcare infrastructure has positioned the region as a leader in precision medicine innovation. The Americas continue to play a pivotal role in pioneering clinical trials and advanced research initiatives, setting benchmarks for other regions on both efficacy and patient safety protocols.

Europe, Middle East and Africa (EMEA) also present a dynamic environment characterized by collaborative research frameworks and a strong emphasis on regulatory harmonization. The region benefits from an established network of research institutions and healthcare facilities that often engage in cross-border partnerships, providing a fertile ground for the development and implementation of advanced precision diagnostic tools and therapies. Simultaneously, the Asia-Pacific region is emerging as a significant player, bolstered by rapid advancements in technology and increasing investments in healthcare innovation. This region has seen a surge in both clinical and commercial activities related to precision medicine, driven by the growing demand for healthcare solutions that cater to diverse genetic backgrounds and emerging health challenges.

These regional insights underscore the importance of localized as well as collaborative global strategies. As precision medicine continues to evolve, stakeholders in each region are increasingly leveraging their unique strengths-be it research expertise, regulatory diligence, or market agility-to contribute to a globally interconnected healthcare ecosystem. This confluence of regional dynamics is fostering innovations that not only enhance patient care on a local level but also contribute to a broader understanding of disease management and therapeutic interventions worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Landscape of Precision Medicine

Several prominent companies are at the forefront of driving innovation in precision medicine. Major industry players such as AbbVie Inc., Amgen Inc., and AstraZeneca PLC are championing new drug discoveries and targeted therapies, while smaller innovative firms like Aranscia, LLC and biocrates life sciences ag are contributing novel approaches to diagnostic and analytics technologies. In addition, bioMerieux S.A. and Bristol-Myers Squibb Company are making significant strides in molecular diagnostics and advanced therapeutic solutions.

Other notable entities such as Caris Life Sciences and Exact Sciences Corporation have established themselves as key contributors in the realm of companion diagnostics and early cancer detection. Leading pharmaceutical giants like F. Hoffmann-La Roche AG, Gilead Sciences, Inc., and Johnson & Johnson are continually investing in breakthrough research and development, further underscoring the importance of precision medicine as an integral component of modern healthcare. Organizations like Laboratory Corporation of America Holdings and Illumina, Inc. exemplify the critical role that diagnostic laboratories and genomic sequencing technologies play in supporting personalized treatment regimens.

The landscape is further enriched by the participation of Medtronic PLC, Merck KGaA, and N-Power Medicine, Inc., who are advancing not only therapeutic interventions but also integrated care solutions that harness both hardware and software innovations. Natera Inc., NeoGenomics, Inc., Novartis AG, and Pfizer, Inc. continue to lead in marrying clinical breakthroughs with large-scale commercial application, while companies such as Precision Medicine Group, LLC, QIAGEN N.V., and Quest Diagnostics Incorporated emphasize the importance of robust data analytics in realizing the full potential of precision therapies. Other influential organizations including Sanofi SA, Strata Oncology, Inc., Tempus AI, Inc., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and ZS Associates, Inc. are making strategic investments that resonate with the evolving demand for patient-specific care modalities.

Collaboration and strategic partnerships among these companies are driving the market forward, creating synergies that not only foster innovation but also enhance the accessibility and impact of precision medicine solutions globally. Their collective efforts are pivotal in advancing a healthcare model that is distinctly tailored to individual patient needs while pushing the boundaries of what is clinically possible.

The report delves into recent significant developments in the Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Aranscia, LLC, AstraZeneca PLC, biocrates life sciences ag, bioMerieux S.A., Bristol-Myers Squibb Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Guardant Health, Inc., healthOme, Inc., Hitachi High-Tech Corporation, Illumina, Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Medtronic PLC, Merck KGaA, N-Power Medicine, Inc., Natera Inc., NeoGenomics, Inc., Novartis AG, Pfizer, Inc., Precision Medicine Group, LLC, QIAGEN N.V., Quest Diagnostics Incorporated, Sanofi SA, Strata Oncology, Inc., Tempus AI, Inc., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and ZS Associates, Inc.. Actionable Recommendations for Navigating the Future of Precision Medicine

Industry leaders are encouraged to adopt a forward-thinking approach that leverages emerging technologies and data-driven methodologies to bridge the gap between current capabilities and future needs. One key recommendation is the investment in state-of-the-art diagnostic infrastructure that integrates genomic sequencing, artificial intelligence, and advanced analytics. By harnessing these tools, organizations can ensure that their diagnostic processes are both accurate and timely, thus facilitating early intervention and personalized treatment.

It is essential to cultivate strategic partnerships that merge expertise across academic research, clinical practice, and technological innovation. Such alliances not only enhance the scope of available resources but also enable a more agile response to regulatory changes and market dynamics. Leaders should also prioritize the development of cross-functional teams that blend clinical insights with data science expertise, ensuring that new products and services are both clinically effective and commercially viable.

Another key recommendation involves the adoption of flexible business models that can adapt to the rapid pace of technological change. Embracing digital transformation is vital, particularly through the integration of innovative software and data analytics tools into everyday clinical operations. This proactive stance will enable organizations to seamlessly incorporate emerging evidence and best practices into their business strategies, paving the way for sustained competitive advantage.

Furthermore, a focus on patient-centric outcomes is crucial. Leaders must ensure that every strategic decision is informed by a commitment to improving patient care quality, which ultimately translates into higher satisfaction and better health outcomes. This may involve reconfiguring service delivery models to include remote monitoring, telehealth services, and personalized care plans that reflect the latest advances in precision medicine.

Finally, continuous education and training initiatives should be implemented to keep the workforce abreast of the latest technological trends and regulatory updates. By fostering an environment of ongoing learning, companies can empower their teams to innovate and adapt, ensuring that the organization remains at the cutting edge of precision medicine innovation.

Conclusion: Embracing a Future Driven by Precision Medicine Innovations

Precision medicine is redefining the boundaries of healthcare with its promise of individualized treatment and targeted therapies. The evolving landscape, marked by groundbreaking technological innovations, dynamic segmentation strategies, and significant regional and corporate contributions, is building a foundation for a healthcare system that is more responsive, efficient, and patient-focused.

This comprehensive analysis has uncovered the transformative shifts that are reshaping both diagnostics and therapeutics, highlighted the critical insights gathered from detailed market segmentation, and illuminated the global regional dynamics that are setting the course for future developments. The role of pioneering companies in driving innovation and forging strategic partnerships demonstrates the collaborative nature of this field, underscoring the need for continuous investment in research, technology, and human capital.

As stakeholders continue to push the envelope of what is possible, it is imperative to remain vigilant and adaptive. The future of precision medicine is not determined solely by scientific breakthroughs but also by an integrated approach that combines technology, regulation, and clinical excellence. The convergence of these elements promises a future where healthcare is not just about treating disease but about enhancing quality of life.

Ultimately, the journey toward a more precise and personalized healthcare model is one of both immense promise and significant challenge. It is a call to action for all industry players to harness the momentum of current innovations and channel it into strategies that drive sustained growth, improved patient outcomes, and an overall transformation of the global healthcare landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases with demand for personalized treatment options
    • 5.1.1.2. Growing awareness among patients and healthcare providers about the benefits of precision medicine
    • 5.1.1.3. Increased government initiatives and public-private funding aimed at advancing precision medicine technologies
  • 5.1.2. Restraints
    • 5.1.2.1. High development cost and lack standardized protocols and guidelines for precision medicine
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence into precision medicine for improved patient diagnosis and therapy
    • 5.1.3.2. Collaborations between market vendors and research institutes to advance precision medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with privacy and the confidentiality of personal and health information of patients
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Foundational role in accurately identifying the molecular and genetic underpinnings of disease increases usage of diagnostics
  • 5.2.2. Application: Widepread usage of precision medicine in oncology due to its ability to tailor therapeutic approaches based on individual genetic, molecular, and clinical profiles
  • 5.2.3. End User: Adoption of precision medicine in biopharmaceutical & biotechnology companies to develop targeted therapies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Precision Medicine Market, by Product Type

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Companion Diagnostics
  • 6.2.2. Genetic Testing
  • 6.2.3. Liquid Biopsy
  • 6.2.4. Molecular Diagnostics
  • 6.2.5. Point-of-Care Testing
• 6.3. Software & Data Analytics
• 6.4. Therapeutics
  • 6.4.1. Cell Therapy
  • 6.4.2. Gene Therapy
  • 6.4.3. Immunotherapy
  • 6.4.4. Protein Replacement Therapy
  • 6.4.5. RNA-Based Therapy
  • 6.4.6. Targeted Therapy

7. Precision Medicine Market, by Application

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Cardiology
• 7.4. Infectious Diseases
• 7.5. Neurology
• 7.6. Oncology
• 7.7. Rare & Genetic Disorders
• 7.8. Respiratory Diseases

8. Precision Medicine Market, by End User

• 8.1. Introduction
• 8.2. Biopharmaceutical & Biotechnology Companies
• 8.3. Diagnostic Laboratories
• 8.4. Hospitals & Clinics
• 8.5. Research Institutes

9. Americas Precision Medicine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Precision Medicine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Precision Medicine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. MB Therapeutics secures Euro 2 million in seed funding to accelerate research and enhance personalized medicine production
  • 12.3.2. Caris Life Sciences announces a strategic collaboration with Ontada to advance oncology research and the adoption of precision medicine
  • 12.3.3. Lupus Research Alliance launches DREAM platform to advance precision medicine
  • 12.3.4. Hitachi High-Tech and Gencurix unite to commercialize advanced cancer molecular diagnostics, accelerating precision medicine
  • 12.3.5. WashU Medicine's Center for Translational Bioinformatics to enhance personalized precision medicine and clinical trials through cutting-edge innovation
  • 12.3.6. Precision for Medicine acquires Algorics to integrate MetaVate and Clarity for enhanced clinical trial execution
  • 12.3.7. Karolinska Institutet, Karolinska University Hospital, and Elekta forge a strategic alliance to transform cancer care through precision diagnostics
  • 12.3.8. Genomic Medicine Sweden receives SEK 49.5 million for precision medicine investments
  • 12.3.9. Siemens Healthineers and IISc launch state-of-the-art AI laboratory to transform precision medicine
  • 12.3.10. BIOS Health partners with local authorities and Kern Venture Group to launch a West Coast precision medicine centre in Bakersfield
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. Novartis AG
  • 12.4.2. Illumina, Inc.
  • 12.4.3. Tempus AI, Inc.
  • 12.4.4. Caris Life Sciences

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Aranscia, LLC
• 4. AstraZeneca PLC
• 5. biocrates life sciences ag
• 6. bioMerieux S.A.
• 7. Bristol-Myers Squibb Company
• 8. Caris Life Sciences
• 9. Exact Sciences Corporation
• 10. F. Hoffmann-La Roche AG
• 11. Gilead Sciences, Inc.
• 12. Guardant Health, Inc.
• 13. healthOme, Inc.
• 14. Hitachi High-Tech Corporation
• 15. Illumina, Inc.
• 16. Johnson & Johnson
• 17. Laboratory Corporation of America Holdings
• 18. Medtronic PLC
• 19. Merck KGaA
• 20. N-Power Medicine, Inc.
• 21. Natera Inc.
• 22. NeoGenomics, Inc.
• 23. Novartis AG
• 24. Pfizer, Inc.
• 25. Precision Medicine Group, LLC
• 26. QIAGEN N.V.
• 27. Quest Diagnostics Incorporated
• 28. Sanofi SA
• 29. Strata Oncology, Inc.
• 30. Tempus AI, Inc.
• 31. Teva Pharmaceutical Industries Ltd.
• 32. Thermo Fisher Scientific Inc.
• 33. ZS Associates, Inc.